IRF8 and hepatocellular carcinoma: Similarly, the IFN-γ and ICIs immune therapies signaling pathway is significantly inhibited with low levels of IRF8 in hepatocellular carcinoma and is associated with poor prognosis (58), while high expression of IRF8 in human breast cancer is associated with better response to immune therapy and chemotherapy (59).